Navigation Links
Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products.
Date:7/31/2013

LYNDHURST, N.J., July 31, 2013 /PRNewswire/ -- Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products. Under the terms of the agreement, Amerigen will use its formulation expertise to develop a range of complex generic products and will commercialize such products in the United States.  Forest will make undisclosed milestone payments to Amerigen and will receive royalties on US sales of such products.  In addition, Forest will have an option to acquire rights to register and commercialize certain products in Latin America.

John Lowry, Amerigen's President & CEO commented: "This collaboration is a testament to Amerigen's generic formulation and product development capabilities and enables the company to continue its efforts to build a portfolio of differentiated, high value generic pharmaceuticals. It also enables Amerigen to leverage its product development investments into an array of fast growing emerging markets, with the support of a leading international pharmaceutical company."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, the Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
2. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
3. Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
5. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
6. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
8. Insight Pharmaceuticals Considers Bananacin -- Banana-Flavored Anacin Tablets -- After Worlds Oldest Man Credits Combo As Secret To Long Life
9. Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ORANGE COUNTY, Calif. , May 5, 2016 ... for nearly a decade due to concerns that ... advances in the approach to imaging, as well ... in a new era of medical peripherals that ... better care.   Ampronix  advanced medical imaging is a ...
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... addition to its family of Partner Firms. Headquartered in Mount Pleasant, South Carolina, ... and health care consumerism specialists. , “Partnering with UBA will enable our firm ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael Lanteri Agency in ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:5/5/2016)... ... May 05, 2016 , ... Tim Dieter ... serving families of greater Dubuque, IA. The current campaign fundraises for Veteran’s Freedom ... veterans. Donations to Veteran’s Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TIME for ... safety – today announced a new partnership to reach nearly 1 million children with ... in an instant and is the leading cause of accidental death in children one ...
(Date:5/5/2016)... ... ... The 2016 Nike Soccer Camp will be directed by the 2015 Big ... they bring their winning Vandals coaching philosophy to young athletes. Programs are offered for ... school players. Session dates are as follows: , Youth Day Camp – July 11th-14th, ...
Breaking Medicine News(10 mins):